Highlights Roche Holding AG London S.E.

Equities

0QQ6

CH0012032113

Market Closed - London S.E. Other stock markets 11:39:09 2024-06-28 EDT			5-day change	1st Jan Change
273.8 ^CHF	-0.29%		-0.92%	+4.74%

06-28	Swiss Market Index Closes Little Changed Amid Key European Inflation Data	MT
06-28	Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Swiss Market Index Closes Little Changed Amid Key European Inflation Data	06-28	MT
Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication	06-28	MT
Roche Gets EU Panel's Backing for Rare Blood Disorder Therapy	06-28	MT
Roche's Vabysmo Wins EMA Panel's Backing for Retinal Vein Occlusion Indication	06-28	MT
Roche's Rare Blood Disorder Drug PiaSky Backed for Approval in EU	06-28	MT
EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older	06-28	RE
Roche Receives Additional Prequalification Designations for HPV Test	06-27	MT
Roche Wins EU Nod for Subcutaneous Formula of Multiple Sclerosis Drug Ocrevus	06-25	MT
Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis	06-25	CI
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis	06-25	CI
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	06-24
Foreign banks target Switzerland after UBS takeover of Credit Suisse	06-24	RE
Roche: two new units for cobas pro	06-24	CF
European Medicines Agency Begins Review of Roche's Gene Therapy for Duchenne Muscular Dystrophy	06-24	MT
US FDA approves Roche's drug for a chronic blood disorder	06-21	RE
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket	06-21	MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours	06-20	MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump	06-20	RE
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys	06-20	DJ
Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above	06-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am